SOAT1 and inflammatory bowel disease: Current therapeutic approaches for IBD, including biologics (e.g., anti-TNFα antibodies such as infliximab and adalimumab) and small-molecule inhibitors (e.g., JAK/STAT pathway blockers like tofacitinib), have significantly improved disease management.